Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)

ROS1 rearrangements are considered rare in non-small-cell lung cancer (NSCLC). This retrospective real-world study aimed to evaluate first-line treatment with crizotinib, a tyrosine kinase inhibitor (TKI) standard of care vs. new generation ROS1 anti-cancer agents. Forty-nine ROS1-expressing NSCLC p...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Urska Janzic, Natalie Maimon Rabinovich, Walid Shalata, Waleed Kian, Katarzyna Szymczak, Rafal Dziadziuszko, Marko Jakopovic, Giannis Mountzios, Adam Pluzanski, Antonio Araujo, Andriani Charpidou, Sameh Daher, Abed Agbarya
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2024-07-01
Rangatū:	Current Oncology
Ngā marau:	first-line treatment non-small-cell lung cancer real-world data ROS1 rearrangements
Urunga tuihono:	https://www.mdpi.com/1718-7729/31/8/326
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!